|
|
Volumn 3, Issue 5, 2011, Pages 415-416
|
|
Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies
a
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABATACEPT;
ADALIMUMAB;
AFLIBERCEPT;
ALEFACEPT;
ANTIRHEUMATIC AGENT;
BELATACEPT;
BELIMUMAB;
BEVACIZUMAB;
BRENTUXIMAB VEDOTIN;
CANAKINUMAB;
CATUMAXOMAB;
CERTOLIZUMAB PEGOL;
CNTO 528;
DENOSUMAB;
ERYTHROPOIETIN;
ETANERCEPT;
EYLEA;
GEMTUZUMAB OZOGAMICIN;
GOLIMUMAB;
HD 203;
HYBRID PROTEIN;
IBRITUMOMAB TIUXETAN;
INFLIXIMAB;
IPILIMUMAB;
NULOJIX;
RANIBIZUMAB;
RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;
RILONACEPT;
RITUXIMAB;
ROMIPLOSTIM;
TOSITUMOMAB I 131;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY;
ANTIGEN BINDING;
BIOLOGICAL ACTIVITY;
COMPLEMENT DEPENDENT CYTOTOXICITY;
DRUG APPROVAL;
DRUG CLEARANCE;
DRUG COST;
DRUG HALF LIFE;
DRUG MARKETING;
DRUG MECHANISM;
EDITORIAL;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
PHAGOCYTOSIS;
RHEUMATOID ARTHRITIS;
ARTHRITIS, RHEUMATOID;
CLINICAL TRIALS AS TOPIC;
HUMANS;
IMMUNOGLOBULIN FC FRAGMENTS;
IMMUNOLOGIC FACTORS;
PEPTIDES;
PSORIASIS;
RECOMBINANT FUSION PROTEINS;
TREATMENT OUTCOME;
TUMOR NECROSIS FACTOR-ALPHA;
VASCULAR ENDOTHELIAL GROWTH FACTOR A;
|
|
EID: 80052569742
PISSN: 19420862
EISSN: 19420870
Source Type: Journal
DOI: 10.4161/mabs.3.5.17334 Document Type: Editorial |
|
Times cited : (152)
|
|
References (0)
|
